Masashi Koto1, Azusa Hasegawa2, Ryo Takagi2, Go Sasahara2, Hiroaki Ikawa2, Jun-Etsu Mizoe2, Keiichi Jingu3, Hirohiko Tsujii2, Tadashi Kamada2, Yoshitaka Okamoto4. 1. Research Center for Charged Particle Therapy Hospital, National Institute of Radiological Sciences, Chiba, Japan. Electronic address: koto@nirs.go.jp. 2. Research Center for Charged Particle Therapy Hospital, National Institute of Radiological Sciences, Chiba, Japan. 3. Department of Radiation Oncology, Tohoku University School of Medicine, Sendai, Japan. 4. Department of Otolaryngology, Chiba University School of Medicine, Japan.
Abstract
BACKGROUND AND PURPOSE: To evaluate the safety and efficacy of carbon ion radiotherapy (CIRT) for locally advanced sinonasal adenocarcinoma. MATERIAL AND METHODS: Twenty-two patients with sinonasal adenocarcinoma were treated with CIRT. CIRT was the primary treatment for 16 patients. Four patients received CIRT for local recurrence after surgery and two for residual tumour after surgery or chemotherapy. At the start of CIRT, 1 patient had T-classification (T) 2 disease, 2 had T3 disease, 5 had T4a disease, and 14 had T4b disease. Fourteen patients were treated with 57.6 Gy equivalent (GyE)/16 fractions, and 8, with 64.0 GyE/16 fractions. RESULTS: The median follow-up period was 43 months for all patients. The 3-year local control and loco-regional control rates for all patients were 76.9% (95% confidence interval [CI]=56.7-97.1%) and 61.3% (95% CI=38.5-84.1%), respectively. The 3-year overall survival and disease-specific survival rates were 59.1% (95% CI=38.6-79.6%) and 65.6% (95% CI=44.9-86.3%), respectively. Acute reactions of grade 3 of the skin and mucosa were observed in 2 and 4 patients, respectively. Late reactions included lateral visual loss (5 patients), mucosal ulceration (1 patient), and brain necrosis with clinical symptoms (1 patient). In the 5 patients who developed visual loss, the optic nerve was close to the tumour. CONCLUSIONS: CIRT was effective and generally safe for locally advanced sinonasal adenocarcinoma.
BACKGROUND AND PURPOSE: To evaluate the safety and efficacy of carbon ion radiotherapy (CIRT) for locally advanced sinonasal adenocarcinoma. MATERIAL AND METHODS: Twenty-two patients with sinonasal adenocarcinoma were treated with CIRT. CIRT was the primary treatment for 16 patients. Four patients received CIRT for local recurrence after surgery and two for residual tumour after surgery or chemotherapy. At the start of CIRT, 1 patient had T-classification (T) 2 disease, 2 had T3 disease, 5 had T4a disease, and 14 had T4b disease. Fourteen patients were treated with 57.6 Gy equivalent (GyE)/16 fractions, and 8, with 64.0 GyE/16 fractions. RESULTS: The median follow-up period was 43 months for all patients. The 3-year local control and loco-regional control rates for all patients were 76.9% (95% confidence interval [CI]=56.7-97.1%) and 61.3% (95% CI=38.5-84.1%), respectively. The 3-year overall survival and disease-specific survival rates were 59.1% (95% CI=38.6-79.6%) and 65.6% (95% CI=44.9-86.3%), respectively. Acute reactions of grade 3 of the skin and mucosa were observed in 2 and 4 patients, respectively. Late reactions included lateral visual loss (5 patients), mucosal ulceration (1 patient), and brain necrosis with clinical symptoms (1 patient). In the 5 patients who developed visual loss, the optic nerve was close to the tumour. CONCLUSIONS: CIRT was effective and generally safe for locally advanced sinonasal adenocarcinoma.
Authors: Osama Mohamad; Brock J Sishc; Janapriya Saha; Arnold Pompos; Asal Rahimi; Michael D Story; Anthony J Davis; D W Nathan Kim Journal: Cancers (Basel) Date: 2017-06-09 Impact factor: 6.639
Authors: Sati Akbaba; Kristin Lang; Thomas Held; Klaus Herfarth; Juliane Rieber; Peter Plinkert; Gerd U Auffarth; Stefan Rieken; Juergen Debus; Sebastian Adeberg Journal: Cancer Manag Res Date: 2019-02-01 Impact factor: 3.989
Authors: Timothy D Malouff; Laura A Vallow; Danushka Seneviratne; Anita Mahajan; Robert L Foote; Bradford Hoppe; Chris Beltran; Steven J Buskirk; Sunil Krishnan; Daniel M Trifiletti Journal: Int J Part Ther Date: 2020-11-05
Authors: Timothy D Malouff; Anita Mahajan; Sunil Krishnan; Chris Beltran; Danushka S Seneviratne; Daniel Michael Trifiletti Journal: Front Oncol Date: 2020-02-04 Impact factor: 5.738